Nature Search

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

Smita K. Nair
David Boczkowski
Eli Gilboa
Research01 Apr 1998
Nature Biotechnology

Volume: 16, P: 364-369
The determinants of tumour immunogenicity

Four leading tumour immunologists provide their opinions on the determinants of immunogenicity and how we might therapeutically improve tumour immunogenicity in the future.

Thomas Blankenstein
Pierre G. Coulie
Elizabeth M. Jaffee
Reviews01 Mar 2012
Nature Reviews Cancer

Volume: 12, P: 307-313
DNase II mediates a parthanatos-like developmental cell death pathway in Drosophila primordial germ cells

Caspase independent alternative cell death (ACD) pathways exist, but have been largely investigated under non-physiological conditions. Here, the authors show that Drosophila primordial germ cells normally elicit DNase II-dependent DNA damage, triggering a parthanatos-like ACD pathway.

Lama Tarayrah-Ibraheim
Elital Chass Maurice
Eli Arama
ResearchOpen Access16 Apr 2021
Nature Communications

Volume: 12, P: 1-20
Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors

Gordon Keller
Christopher Paige
Erwin F. Wagner
Research14 Nov 1985
Nature

Volume: 318, P: 149-154
Cell–surface markers for assessing gene transfer into human hematopoietic cells

Kenneth Philips
Tracy Gentry
Clay Smith
Advertorial01 Oct 1996
Nature Medicine

Volume: 2, P: 1154-1156
Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Smita K. Nair
Axel Heiser
Eli Gilboa
Research01 Sept 2000
Nature Medicine

Volume: 6, P: 1011-1017
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

The main reason why tumours are not controlled by the immune system is that they do not express potent tumour rejection antigens. Tumour vaccination aims to provoke a response to any antigens that are expressed. Here, a new approach is described: nonsense-mediated messenger RNA decay in tumour cells is inhibited, leading to the expression of new antigens and to significant inhibition of tumour growth in mice.

Fernando Pastor
Despina Kolonias
Eli Gilboa
Research13 May 2010
Nature

Volume: 465, P: 227-230
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity

The anti-tumour immune response greatly depends on the number of tumour neoantigens. Here the authors show in mouse models that a therapeutic strategy aimed at increasing the number of neoantigens via downregulating TAP, an antigen processing associated protein, enhances anti-tumour immunity and the efficacy of immunotherapy.

Greta Garrido
Brett Schrand
Eli Gilboa
ResearchOpen Access21 Aug 2019
Nature Communications

Volume: 10, P: 1-13
The promise of cancer vaccines

Eli Gilboa
Reviews01 May 2004
Nature Reviews Cancer

Volume: 4, P: 401-411
Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

Brett Schrand
Emily Clark
Eli Gilboa
Amendments and CorrectionsOpen Access22 Nov 2021
Nature Communications

Volume: 12, P: 1-2
Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

Efficient tumor antigen uptake by dendritic cells is facilitated by antibody coating of tumor cells. Here, the authors develop an approach based on hapten vaccination and hapten/tumor targeting ligand conjugates that potentiate anti-tumor immunity by generating and redirecting serum antibodies to tumors.

Brett Schrand
Emily Clark
Eli Gilboa
ResearchOpen Access22 Aug 2018
Nature Communications

Volume: 9, P: 1-10
The risk of autoimmunity associated with tumor immunotherapy

The development of increasingly powerful methods to stimulate anti-tumor immune responses carries the risk of breaking tolerance to self and causing autoimmune pathology. How concerned should we be?

Eli Gilboa
Comments & Opinion01 Sept 2001
Nature Immunology

Volume: 2, P: 789-792
Knocking the SOCS1 off dendritic cells

siRNA-mediated inhibition of SOCS1 function enhances the immunostimulatory capacity of dendritic cells and may lead to more effective cancer vaccines.

Eli Gilboa
News & Views01 Dec 2004
Nature Biotechnology

Volume: 22, P: 1521-1522
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

James O McNamara II
Eran R Andrechek
Paloma H Giangrande
Research25 Jun 2006
Nature Biotechnology

Volume: 24, P: 1005-1015
Emerging clinical applications of RNA

Bruce A. Sullenger
Eli Gilboa
Reviews11 Jul 2002
Nature

Volume: 418, P: 252-258
An RNA toolbox for cancer immunotherapy

In this Review, Pastoret al. provide an overview of RNA-based agents used in cancer immunotherapy — ranging from RNA vaccines encoding cancer neoantigens to interference RNAs and protein-binding RNA aptamers — providing insights into this emerging field.

Fernando Pastor
Pedro Berraondo
Ignacio Melero
Reviews07 Sept 2018
Nature Reviews Drug Discovery

Volume: 17, P: 751-767
Correction: Corrigendum: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells

Ming-Da Zhou
Sijie Hao
Si-Yang Zheng
Amendments and Corrections27 Jan 2015
Scientific Reports

Volume: 5, P: 1
Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells

Ming-Da Zhou
Sijie Hao
Si-Yang Zheng
ResearchOpen Access09 Dec 2014
Scientific Reports

Volume: 4, P: 1-11

Search

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA

The determinants of tumour immunogenicity

DNase II mediates a parthanatos-like developmental cell death pathway in Drosophila primordial germ cells

Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors

Cell–surface markers for assessing gene transfer into human hematopoietic cells

Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.

Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay

Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity

The promise of cancer vaccines

Author Correction: Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

The risk of autoimmunity associated with tumor immunotherapy

Knocking the SOCS1 off dendritic cells

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

Emerging clinical applications of RNA

An RNA toolbox for cancer immunotherapy

Correction: Corrigendum: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells

Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells

Search

Quick links

Search

Filter By:

Search

Quick links